Objective: To determine the prevalence, risk factors, and functional impairment associated with peripheral neuropathy in a prospective cohort of adults in rural Uganda.
Neurologic complications of HIV infection are common, and peripheral neuropathy is the most common neurologic disorder among HIV1 adults. 1, 2 Large systematic studies of neuropathy from resource-constrained settings are lacking, and available studies report widely varying neuropathy rates (e.g., 4% in South Africa, 59% in Rwanda). 3, 4 Importantly, neuropathy rates and severity in resource-constrained settings may differ from those seen in Western contexts because of different antiretroviral (ARV) initiation guidelines, a limited range of available ARV drugs, differences in diet and nutrition, unique environmental exposures, use of other neurotoxic medications such as isoniazid, and differing rates of comorbidities. A better understanding of neuropathy prevalence and risk factors in sub-Saharan African populations are crucial as this is where the majority of the world's HIV1 individuals reside. The WHO estimates that almost 26 million people in sub-Saharan Africa are living with HIV, accounting for 70% of the world's 37 million HIV1 persons. 5 Improved knowledge of neuropathy risk factors in this population is imperative to reduce the burden of disease and develop better future treatments for neuropathy.
The goal of this study was to determine the rate of and risk factors for neuropathy among both HIV1 and demographically matched HIV2 adults in rural Uganda, a country with a national HIV prevalence of 7.1% and approximately 1.5 million HIV1 persons in 2015. 6 This represents the largest study to date of ARV-naive HIV1 adults in an outpatient setting in rural sub-Saharan Africa.
METHODS Study participants. Study participants were drawn from the Rakai Community Cohort Study, an open, community-based cohort of adults residing in 50 communities in Rakai District, which is representative of rural Uganda. Eligible participants were $20 years old and in 1 of 3 patient groups: (1) HIV1 ARV-naive adults with advanced immunosuppression (CD4 #200 cells/mL); (2) HIV1 ARV-naive adults with moderate immunosuppression (CD4 350-500 cells/mL); and (3) HIV2 adults who were age-, sex-, and community-matched to the HIV1 participants. (This cohort was also designed to study the effect of HIV subtype on the development of HIV-associated neurocognitive disorders [HAND] . The CD4 strata were used to select participants for assessment of HAND and were not selected specifically for this substudy of neuropathy.) Exclusion criteria included severe systemic illness, inability to provide informed consent, physical disability resulting in an inability to travel to the main Rakai Health Sciences Program clinic, and plans to leave Rakai District within 2 years of enrollment. Leprosy was not a specific exclusion criterion, but no patients with obvious skin lesions of leprosy were included in the study. In addition, while leprosy still occurs in Uganda, it primarily occurs in northern parts of the country and is uncommon in Rakai District, which is located in the south-central region. 11 The Modified Total Neuropathy Scale was also administered.
12,13 A Ugandan medical officer (i.e., a physician who has completed an internship but no residency training) who was trained specifically for the evaluation of peripheral neuropathy by 2 US neurologists (D.S., N.S.) performed a neuromedical evaluation including assessment of subjective neuropathy symptoms and examination of strength, ankle reflexes, vibratory sensation, and pinprick sensation. Participants also underwent a peripheral blood draw for confirmation of HIV status and, in HIV1 participants, for determination of CD4 cell count. Fasting glucose, comprehensive metabolic panels, and fasting lipids were also obtained for each participant.
Standard protocol approvals, registrations, and patient consents. Written informed consent for participating in the Statistical analysis. Peripheral neuropathy was defined as $1 subjective neuropathy symptom (numbness, paresthesias, or pain in the hands or feet) and $1 sign of neuropathy (distal weakness, reduced or absent ankle reflexes, abnormal distal vibratory sensation, or abnormal distal pinprick sensation) on examination. This definition was chosen to minimize false-positives as many participants reported transient tingling but had no objective signs of neuropathy on examination. In addition, because many participants did not regularly wear shoes or regularly engage in manual labor, there was concern that foot calluses would interfere with portions of the sensory examination. As such, the decision was made to require both signs and symptoms in the definition of neuropathy.
Comparative analyses between participant groups and between participants with and without neuropathy were performed using x 2 tests for categorical variables and t tests for continuous variables. Log-binomial regression was performed to determine significant predictors of neuropathy. Analyses were performed using STATA version 10.1 (StataCorp, College Station, TX).
RESULTS Eight hundred participants were enrolled, of whom 400 were HIV2, 200 were HIV1 with advanced immunosuppression (CD4 count ,250 cells/mL), and 200 were HIV1 with moderate immunosuppression (CD4 count 350-500 cells/ mL) (table 1) . Of all participants, 53% were male with a mean (SD) age of 35 (8) Severe neuropathy
Neuropathic symptoms and signs were common in the cohort, with each occurring in approximately one-third of patients (table 2) . However, both were more common among HIV1 than HIV2 participants. Overall, 31% of participants reported neuropathic pain symptoms (HIV1 40%; HIV2 22%; p , 0.001) and 33% of participants had objective signs of neuropathy on examination (HIV1 40%; HIV2 26%; p , 0.001). Because the definition of peripheral neuropathy required the presence of both symptoms and signs, 13% of participants overall met this criterion, which was significantly more common among HIV1 (19%) than HIV2 participants (7%, p , 0.001). HIV1 participants were more likely to have moderate or severe neuropathy than their HIV2 counterparts as assessed by the Modified Total Neuropathy Score.
Risk factors for neuropathy are shown in 
Participants with peripheral neuropathy showed significant functional impairment by multiple measures when compared to participants without neuropathy (table 4). In the overall cohort, participants with neuropathy were more likely to report fatigue (32% vs
DISCUSSION This study of adults in rural Uganda revealed high rates of symptomatic neuropathy (19%) among HIV1 participants with an additional 20% of participants having objective signs but no symptoms of neuropathy. This rate is within the range of those found in other studies of HIVassociated peripheral neuropathy from sub-Saharan Africa, which ranged from 4% among HIV1 ARVnaive South African adults to 60% among HIV1 Rwandan outpatients on ARV therapy. 3, 4 However, most prior studies have found neuropathy rates of Table 3 Risk factors associated with neuropathy by patient group Overall population (n 5 800) HIV1 population (n 5 400) HIV2 population (n 5 400) 21, 22 Much of the variability likely results from the diversity of patient populations studied as most cohorts included both ARV-naive HIV1 participants and those who had initiated ARV therapy. Study settings varied from exclusively outpatient to inpatient settings, and some included participants from both settings. In addition, the methods used to diagnose neuropathy varied widely from assessment by a neurologist to diagnoses based on peripheral neuropathy screening tools. The most commonly used screening tools were the Brief Peripheral Neuropathy Screen and Subjective Peripheral Neuropathy Screen, which have primarily been validated in the United States but have variable diagnostic utility in resource-limited settings. 15, 16, 20, 23, 24 A South African study of HIV1 outpatients, which included both ARV-naive and ARV-experienced participants, identified symptomatic neuropathy in 30% of participants with 50% of participants having objective signs of neuropathy on examination. 25 These findings are similar to this study, in which 19% of participants had symptomatic neuropathy and 40% had objective signs of neuropathy. The slightly higher rates observed in the South African participants may be attributable to neurotoxic effects of ARV therapy as many first-line ARV medications in sub-Saharan Africa, such as stavudine, confer additional risk of developing neuropathy. Similar differences were found in Kenyan cohorts, in which neuropathy rates rose from 11% in ARV-naive to 36% among HIV1 ARV-experienced outpatients. 16, 17 These findings suggest that neuropathy rates among HIV1 adults in rural Uganda who have initiated ARV therapy may be even higher than those reported in this study.
Of note, 7% of HIV2 participants in our cohort met criteria for neuropathy, with an additional 20% of HIV2 participants having objective signs of neuropathy on examination without concurrent symptoms. These rates were much higher than expected given that this cohort included relatively young and healthy adults with low rates of diabetes, renal disease, and liver disease. A prior study of HIV1 participants matched to HIV2 controls in Nigeria found no cases of neuropathy among the 100 controls they studied. 19 Epidemiologic data of overall peripheral neuropathy rates not linked to one particular etiology are sparse. However, a population-based study in Bombay in which participants who screened positive for neuropathy symptoms on a door-to-door survey were evaluated by a neurologist found an overall neuropathy prevalence of 2.4%, which is much lower than that observed in Rakai. 26 Furthermore, many known neuropathy risk factors, including alcohol use, height, and prior neurotoxic medication use, were not associated with neuropathy risk in this study, suggesting that other unstudied risk factors may account for high rates of neuropathy observed in this cohort. Nutritional deficiencies, environmental exposures, and other infectious etiologies may at least partially account for the high neuropathy rate observed in this study but were not assessed in this cohort.
Among HIV1 participants in Rakai, older age was associated with neuropathy. Older age was significantly associated with increased neuropathy risk in other HIV1 cohorts in Uganda, Zimbabwe, Kenya, and Ethiopia. 14, 16, 17, 19, 21, 22 Female sex was also associated with higher risk of neuropathy in all subgroups, although this association was only significant among the overall cohorts. Overall, the effect of sex on neuropathy is controversial. Studies from Kenya, Uganda, and Zimbabwe report an increased neuropathy risk among female participants, but other cohorts from Uganda, Zimbabwe, and Nigeria have found no association. 14, 21, 22 One study of 150 HIV1 Kenyan outpatients initiating ARV therapy found that women were at 10-fold increased risk of developing neuropathy after ARV initiation than their male counterparts, an effect that was partially attenuated Table 4 Relationship of fatigue, motor, depression, and functional impairment to neuropathy by patient group, mean (SD) by the increased neuropathy risk associated with low hemoglobin levels. 17 A study of both HIV1 and HIV2 adult women in Rwanda found that approximately half of women in both groups reported neuropathy symptoms. 27 These rates were so much higher than expected that the authors posit the rates must be due to overreporting among women, although no objective measures of neuropathy were evaluated to validate this claim. In our study, the diagnosis required both subjective symptoms and objective signs of neuropathy. However, there was no difference in rates of objective signs of neuropathy by sex, which suggests that women may be more likely to report neuropathy symptoms than men. The absence of a sex difference in objective signs of neuropathy observed in this cohort suggests underreporting of symptoms by men rather than overreporting by women.
One unexpected finding in this study was that there was no relationship between CD4 count and neuropathy. In the United States, markers of HIV disease severity, such as low CD4 count and high viral load, have consistently been linked to neuropathy risk. 28, 29 Studies from sub-Saharan Africa have found no association between CD4 count or duration of HIV infection with peripheral neuropathy. 4, 19, 22, 25 Taken together, these findings suggest that factors other than those related to HIV disease severity may be contributing to neuropathy rates in sub-Saharan Africa.
Peripheral neuropathy among both HIV1 and HIV2 participants in Rakai was significantly linked to poorer functional status, as has been previously observed in the United States and in other regions of sub-Saharan Africa. For example, in the CNS HIV Antiretroviral Therapy Effects Research Study (CHARTER), neuropathy was associated with reduced quality of life, unemployment, and disability in activities of daily living. 29 Another cohort of nearly 1,000 HIV1 adults in the United States found that neuropathy was associated with worsened health status, decreased work productivity, and increased health care utilization. 30 While a study from Nigeria found no association between neuropathy and overall mortality in HIV1 adults, a Rwandan study found that neuropathy was associated with reduced quality of life in both physical and psychological domains. 19, 20 This study has several limitations. First, the diagnosis of peripheral neuropathy was based entirely on clinical findings. Given the resource limitations in rural Uganda, we were unable to obtain skin biopsies, nerve conduction studies, quantitative sensory testing, or other electrophysiologic measures of neuropathy to correlate with the clinical data obtained. In addition, the neurologic evaluation was completed by nonneurologist physicians. However, these physicians received in-person training on assessing neuropathy signs from US-trained neurologists (D.S., N.S.) before the study began and at regular intervals throughout the study. Concomitant diagnoses of conditions predisposing to neuropathy, such as diabetes and thyroid dysfunction, were based only on self-report and are likely underdiagnosed in this rural setting. In addition, our study did not include measures of nutritional status, such as dietary surveys, household income information, or laboratory markers such as mean corpuscular volume. As a result, nutritional deficiencies as risk factors for neuropathy, which may be important contributors in this population, were not fully addressed. Finally, given local resource constraints, a thorough laboratory investigation to assess for causes of peripheral neuropathy was not possible.
This study is important for several reasons. First, it represents one of the largest systematic assessments of peripheral neuropathy in rural sub-Saharan Africa. Inclusion of age-, sex-, and community-matched HIV2 participants also offered the opportunity to compare predisposing factors for neuropathy while adequately controlling for the effect of HIV. Furthermore, investigating the prevalence of neuropathy in an ambulatory population is more likely to accurately represent the true population prevalence because neuropathies associated with acute illnesses, which may be common in hospitalized patients, are not included. Finally, the frequency of neuropathy in the HIV1 individuals is not confounded by the use of neurotoxic ARV therapy as all HIV1 individuals were ARV-naive at the time of evaluation.
Given the high rates of neuropathy seen in our study and others from sub-Saharan Africa as well as the significant association of neuropathy with lost productivity, worsened health status, and reduced quality of life, HIV2associated neuropathy is likely a major cause of morbidity in sub-Saharan Africa and likely contributes substantially to lost productivity and health care utilization in this region. Further investigation is needed to determine unique risk factors for neuropathy in both HIV1 and HIV2 adults in this region, and the effect of ARV therapy on neuropathy for the HIV1 individuals. In addition, research is urgently needed to improve the treatment of neuropathy in order to reduce the negative effects of neuropathy at an individual, family, community, and societal level in sub-Saharan Africa.
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